Literature DB >> 1815044

Estimation of amobarbital plasma-effect site equilibration kinetics. Relevance of polyexponential conductance functions.

J W Mandema1, P Veng-Pedersen, M Danhof.   

Abstract

The time delay between drug plasma concentrations and effect has been modeled most commonly by the effect compartment approach, assuming first-order monoexponential equilibrium kinetics between plasma and effect site. So far this assumption has not been rigorously probed. The purpose of the present investigation was to model the delay between amobarbital plasma concentrations and EEG effect using a new approach based on system analysis principles. This approach models the equilibrium between plasma and effect site without assuming a specific kinetic structure. Assuming linear distribution kinetics between plasma and effect site, the relationship between the two variables may be described by a convolution type of linear operation, involving a conductance function phi(t), which is approximated by a sum of exponentials. Six male Wistar-derived rats received an iv infusion of amobarbital at a rate of 10 mg/kg per min until isoelectric periods of 5 sec or longer appeared on the EEG. Frequent arterial blood samples were obtained and EEG was continuously quantified using aperiodic analysis. The amplitudes in the 2.5-30 Hz frequency band were used as EEG effect measure. The delay between plasma concentrations and EEG effect was best modeled by a biexponential conductance function. The use of a biexponential conductance function resulted in a significant further reduction (41 +/- 10%) in hysteresis when compared to a monoexponential function, indicating that the assumption of simple first-order monoexponential equilibration kinetics is inadequate. The use of a biexponential conductance function also resulted in a significantly different shape of the effect site concentration-EEG effect relationship and hence the estimated pharmacodynamic parameters, when compared with a monoexponential function. This relationship showed a biphasic behavior, with EEG effects being maximal at amobarbital concentrations of 29.6 +/- 1.3 mg/L. At 80.2 +/- 2.0 mg/L the EEG effect was reduced 50% below baseline values. A comparison was made with the equilibration between amobarbital plasma and cerebrospinal fluid (CSF) concentrations. Six male Wistar-derived rats received an iv infusion of amobarbital, 10 mg per min for 15 min. Arterial blood and CSF samples were taken simultaneously at regular intervals. The equilibration between plasma and CSF concentrations was best fitted by a monoexponential conductance function. Significant differences in equilibration profiles of CSF and effect site with the plasma site were observed. To reach 50% equilibrium the effect site requires 2.5 +/- 0.3 min and the CSF 3.5 +/- 0.2 min, to reach 95% the values were, respectively, 90 +/- 27 and 15 +/- 1 min. This suggests that CSF is kinetically distinguishable from the effect site.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1815044     DOI: 10.1007/BF01080870

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  24 in total

1.  Biophase equilibration times.

Authors:  P Veng-Pedersen; J W Mandema; M Danhof
Journal:  J Pharm Sci       Date:  1991-09       Impact factor: 3.534

2.  Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of heptabarbital using aperiodic EEG analysis.

Authors:  J W Mandema; M Danhof
Journal:  J Pharmacokinet Biopharm       Date:  1990-10

3.  Strategy to assess the role of (inter)active metabolites in pharmacodynamic studies in-vivo: a model study with heptabarbital.

Authors:  J Dingemanse; D Thomassen; B H Mentink; M Danhof
Journal:  J Pharm Pharmacol       Date:  1988-08       Impact factor: 3.765

4.  Semiparametric approach to pharmacokinetic-pharmacodynamic data.

Authors:  D Verotta; S L Beal; L B Sheiner
Journal:  Am J Physiol       Date:  1989-04

5.  Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models.

Authors:  J D Unadkat; F Bartha; L B Sheiner
Journal:  Clin Pharmacol Ther       Date:  1986-07       Impact factor: 6.875

6.  Kinetics of interaction between drugs and biological systems.

Authors:  G Segre
Journal:  Farmaco Sci       Date:  1968-10

Review 7.  Pharmacokinetic and pharmacodynamic modeling in vivo.

Authors:  N H Holford; L B Sheiner
Journal:  Crit Rev Bioeng       Date:  1981

8.  Pharmacodynamic characterization of the electroencephalographic effects of thiopental in rats.

Authors:  W F Ebling; M Danhof; D R Stanski
Journal:  J Pharmacokinet Biopharm       Date:  1991-04

9.  Pharmacodynamic modeling of thiopental anesthesia.

Authors:  D R Stanski; R J Hudson; T D Homer; L J Saidman; E Meathe
Journal:  J Pharmacokinet Biopharm       Date:  1984-04

10.  EEG quantitation of narcotic effect: the comparative pharmacodynamics of fentanyl and alfentanil.

Authors:  J C Scott; K V Ponganis; D R Stanski
Journal:  Anesthesiology       Date:  1985-03       Impact factor: 7.892

View more
  9 in total

Review 1.  Electroencephalogram effect measures and relationships between pharmacokinetics and pharmacodynamics of centrally acting drugs.

Authors:  J W Mandema; M Danhof
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

2.  Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patients.

Authors:  Simone van Kralingen; Jeroen Diepstraten; Mariska Y M Peeters; Vera H M Deneer; Bert van Ramshorst; René J Wiezer; Eric P A van Dongen; Meindert Danhof; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2011-11-01       Impact factor: 6.447

Review 3.  Pharmacokinetic-pharmacodynamic modelling: history and perspectives.

Authors:  Chantal Csajka; Davide Verotta
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-01-11       Impact factor: 2.745

4.  Influence of different fat emulsion-based intravenous formulations on the pharmacokinetics and pharmacodynamics of propofol.

Authors:  E H Cox; C A Knibbe; V S Koster; M W Langemeijer; E E Tukker; R Lange; P F Kuks; H J Langemeijer; L Lie-A-Huen; M Danhof
Journal:  Pharm Res       Date:  1998-03       Impact factor: 4.200

5.  Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.

Authors:  Christopher Louizos; Jaime A Yáñez; M Laird Forrest; Neal M Davies
Journal:  J Pharm Pharm Sci       Date:  2014       Impact factor: 2.327

6.  Relationship between etomidate plasma concentration and EEG effect in the rat.

Authors:  P De Paepe; G Van Hoey; F M Belpaire; M T Rosseel; P A Boon; W A Buylaert
Journal:  Pharm Res       Date:  1999-06       Impact factor: 4.200

7.  Tissue distribution of fentanyl and alfentanil in the rat cannot be described by a blood flow limited model.

Authors:  S Björkman; D R Stanski; H Harashima; R Dowrie; S R Harapat; D R Wada; W F Ebling
Journal:  J Pharmacokinet Biopharm       Date:  1993-06

8.  Influence of biophase distribution and P-glycoprotein interaction on pharmacokinetic-pharmacodynamic modelling of the effects of morphine on the EEG.

Authors:  D Groenendaal; J Freijer; D de Mik; M R Bouw; M Danhof; E C M de Lange
Journal:  Br J Pharmacol       Date:  2007-04-30       Impact factor: 8.739

9.  Semiparametric analysis of non-steady-state pharmacodynamic data.

Authors:  D Verotta; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1991-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.